Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

BACKGROUND: Recombinant factor VIIa (rFVIIa) is approved for use in controlling bleeding episodes in people with hemophilia who have developed inhibitors to replacement therapy. Due to its short half-life (t(½)), frequent injections are required, limiting its use as a prophylactic treatment. A novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zollner, S, Schuermann, D, Raquet, E, Mueller-Cohrs, J, Weimer, T, Pragst, I, Dickneite, G, Schulte, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Coagulation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166693/
https://www.ncbi.nlm.nih.gov/pubmed/24641308
http://dx.doi.org/10.1111/jth.12477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166693/
https://www.ncbi.nlm.nih.gov/pubmed/24641308
http://dx.doi.org/10.1111/jth.12477

Ejemplares similares